Establishment Labs Q3 revenue $40.2M, cuts 2024 guidance to $165-168M, raises $50M in direct offering

ESTABLISHMENT LABS HOLDINGS INC.

2024-Q3 EPS reported -$1.80 revenue$121,511,000

Q3 revenue $40.2M vs $38.5M YoY; net loss $16.7M vs $29.3M loss YoY; adjusted EBITDA loss $7.0M vs $16.3M loss.
2024 revenue guidance reduced to $165-168M from prior $174-184M due to FDA delay and Brazil weakness.
Cash $39.7M at Sep 30; pro forma $114M after $25M Oaktree draw and $50M registered direct offering (5% discount).
FDA approved Motiva Implants Sep 26; U.S. launch added 250+ accounts in first three weeks; expects >$35M U.S. revenue in 2025.
Oaktree facility amended: $25M Tranche D available through Dec 31, 2025 subject to revenue milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.